PET/CT for the diagnosis, staging and restaging of prostate cancer

Imaging in Medicine

Volumn 3, Issue 5, 2011, Pages 571-585

  Souvatzoglou, Michael ^a   Gaertner, Florian C ^a   Schwarzenboeck, Sarah ^a   Beer, Ambros J ^a   Schwaiger, M ^a   Krause, Bernd J ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

11C choline PET CT; imaging of prostate cancer; PET CT; prostate cancer; recurrence of prostate cancer

Indexed keywords

CHOLINE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; TRACER;

ANTIGEN SPECIFICITY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 80054941113     PISSN: 17555191     EISSN: 17555205     Source Type: Journal    
DOI: 10.2217/iim.11.48     Document Type: Review

References (92)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581-592 (2007).
2. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J. Clin. 57(2), 90-104 (2007).
3. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur. Urol. 36(1), 31-35 (1999).
4. Morris MJ, Akhurst T, Osman I et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59(6), 913-918 (2002).
5. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J. Nucl. Med. 43(1), 46-55 (2002).
6. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur. J. Nucl. Med. Mol. Imaging 34(2), 185-196 (2007).
7. Dehdashti F, Picus J, Michalski JM et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging 32(3), 344-350 (2005).
8. Kotzerke J, Prang J, Neumaier B et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur. J. Nucl. Med. 27(9), 1415-1419 (2000).
9. 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 45(3), 366-373 (2004).
10. 11C-methionine positron emission tomography. J. Urol. 173(1), 66-69; discussion 69 (2005).
11. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J. Clin. Oncol. 24(16), 2513-2519 (2006).
12. 3) spatial resolution. Radiology 198(3), 795-805 (1996).
13. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2(1-2), 166-189 (2000).
14. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 21(6), 937-946 (2002).
15. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Comm. 296(3), 580-583 (2002).
16. 18fluorine-labeled deoxyglucose. J. Urol. 155(3), 994-998 (1996).
17. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose. Radiology 199(3), 751-756 (1996).
18. Fanti S, Nanni C, Ambrosini V, Gross MD, Rubello D, Farsad M. PET in genitourinary tract cancers. Q. J. Nucl. Med. Mol. Imaging 51(3), 260-271 (2007).
19. Yoshimoto M, Waki A, Yonekura Y et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl. Med. Biol. 28(2), 117-122 (2001).
20. 11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 29(11), 1492-1495 (2002).
21. Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J. Nucl. Med. 43(2), 181-186 (2002).
22. 1H-MR spectroscopy. J. Nucl. Med. 51(11), 1676-1683 (2010).
23. 11C] choline uptake in prostate cancer: a PET study. Eur. J. Nucl. Med. Mol. Imaging 31(3), 317-324 (2004).
24. 18F-fluorocholine PET. J. Nucl. Med. 47(2), 262-269 (2006).
25. 11C]choline PET/CT.
26. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur. J. Nucl. Med. Mol. Imaging 32(7), 742-748 (2005).
27. 11C]choline PET/CT.
28. 11C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur. J. Nucl. Med. Mol. Imaging 35(6), 1065-1073 (2008).
29. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J. Urol. 176(3), 954-960; discussion 960 (2006).
30. 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 34(1), 45-53 (2007).
31. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J. Urol. 153(5), 1496-1498 (1995).
32. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J. Urol. 159(4), 1247-1250 (1998).
33. 18F-choline PET/CT in patients with elevated PSA level and negative prostate needle biopsy for localisation of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 35(5), 976-983 (2008).
34. 18F- fluorocholine PET in men with persistently elevated PSA levels. Eur. J. Nucl. Med. Mol. Imaging 35(8), 1567-1569; author reply 1570 (2008).
35. 11C-choline positron emission tomography. Eur. Urol. 42(1), 18-23 (2002).
36. 11C-choline PET. J. Nucl. Med. 44(3), 331-335 (2003).
37. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur. Urol. 54(2), 392-401 (2008).
38. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 243(1), 28-53 (2007).
39. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J. Urol. 158(3 Pt 1), 687-698 (1997).
40. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 12(2), 181-191 (2011). Discusses hybrid imaging of recurrent prostate cancer with a focus on MR/PET.
41. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur. J. Radiol. 72(3), 381-387 (2009).
42. Eiber M, Beer AJ, Holzapfel K et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest. Radiol. 45(1), 15-23 (2010).
43. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin. Oncol. R. Coll. Radiol. 22(1), 46-55 (2010).
44. Johnstone PA, Tarman GJ, Riffenburgh R, Rohde DC, Puckett ML, Kane CJ. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol. Oncol. 3(4), 108-112 (1997).
45. 11C-choline positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 77(1), 160-164 (2010).
46. 11C]choline PET/CT in prostate cancer recurrence.
47. 18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur. J. Nucl. Med. Mol. Imaging 33(12), 1387-1398 (2006).
48. 18F]-choline PET/CT for staging and restaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 35(2), 253-263 (2008).
49. 11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J. Urol. 27(5), 619-625 (2009).
50. Schmid DT, John H, Zweifel R et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 235(2), 623-628 (2005).
51. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int. 99(6), 1415-1420 (2007).
52. 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol. Int. 70(4), 311-315 (2003).
53. 11C]choline PET.
54. 18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin. Cancer Res. 11(13), 4761-4769 (2005).
55. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J. Nucl. Med. 44(4), 549-555 (2003).
56. 18F-FDG in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 30(4), 607-611 (2003).
57. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 29(10), 1380-1384 (2002).
58. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67(5), 996-1000 (2006).
59. 11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 100(4), 786-793 (2007).
60. 11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur. Urol. 52(2), 423-429 (2007).
61. 11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 35(1), 9-17 (2008).
62. 11C]choline-PET/CT depends on the serum PSA value in patients with biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 35(1), 18-23 (2008).
63. 11C]choline PET/CT in prostate cancer recurrence.
64. Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25(15), 2035-2041 (2007).
65. 11C]choline PET/CT in prostate cancer recurrence.
66. 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother. Oncol. 99(2), 193-200 (2011).
67. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42(1), 25-30 (2003).
68. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277(6), 467-471 (1997).
69. Wall HV. Nuclear Medicine in Clinical Diagnosis and Treatment. Second Edition. Murray IPC, Ell PJ (Eds). Churchill Livingstone, volume 2, 1176 (1998).
70. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J. Nucl. Med. 3, 332-334 (1962).
71. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin. Nucl. Med. 37(6), 462-469 (2007).
72. 18F PET. J. Nucl. Med. 40(10), 1623-1629 (1999).
73. 18F-fluoride PET/CT. J. Nucl. Med. 45(2), 272-278 (2004).
74. 18F-fluoride PET/CT. J. Nucl. Med. 47(2), 287-297 (2006).
75. 18F fluoride PET-CT: a comparative study. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1766-1774 (2008).
76. 11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl. Med. Biol. 35(6), 689-695 (2008).
77. 11C]Choline PET/CT. Clin. Nucl. Med. 35(9), 701-703 (2010).
78. 11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. Eur. J. Nucl. Med. Mol. Imaging 37(10), 1861-1868 (2010).
79. 18fluorine fluorocholine positron emission tomography. J. Urol. 173(1), 252-255 (2005).
80. Steuber T, Schlomm T, Heinzer H et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur. J. Cancer 46(2), 449-455 (2010).
81. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254(3), 925-933 (2010).
82. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol. Int. 74(3), 214-220 (2005).
83. Li X, Liu Q, Wang M et al. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin. Nucl. Med. 33(10), 671-676 (2008).
84. 18F-fluorodeoxyglucose PET and MR imaging. J. Magn. Reson. Imaging 31(5), 1151-1156 (2010).
85. Heinisch M, Dirisamer A, Loidl W et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol. Imaging Biol. 8(1), 43-48 (2006).
86. 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol. Med. 113(6), 895-904 (2008).
87. 18F- fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin 48(1), 1-9; quiz N2-3 (2009).
88. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur. Urol. 44(1), 32-38; discussion 38-39 (2003).
89. 11C-Coline-positron emission tomography/computerized tomography (C-PET/CT) for tumor localization of locally recurrent prostate cancer after radiation therapy. Eur. Urol. (Suppl. 6), 229 (2007).
90. 11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol. Int. 81(2), 191-197 (2008).
91. 11C]choline PET/CT in prostate cancer recurrence.
92. 11C- choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol. Imaging Biol. 12(2), 210-217 (2010).